SCHEDULE: Nantahala Capital Management Reports Stake in Yarrow Bioscience

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has filed a Schedule 13G, disclosing beneficial ownership of 39,198 shares of Yarrow Bioscience, Inc. common stock, representing 0.46% of the class.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed an amendment to their Schedule 13G filing.
• As of September 30, 2026, the Reporting Persons collectively beneficially own 39,198 shares of Yarrow Bioscience, Inc. common stock.
• This ownership stake represents 0.46% of the total outstanding shares of the company's common stock.
• The filing indicates that Nantahala Capital Management, LLC is an investment adviser, and Messrs. Harkey and Mack are control persons of Nantahala.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake below the threshold that typically triggers significant market reaction.

Positives

• The filing confirms a passive investment stake by Nantahala Capital Management, indicating a potential belief in the company's long-term value without seeking control.
• The reporting persons are acting in the ordinary course of business, which is a standard and expected practice for investment firms.

Negatives

• The ownership stake is very small (0.46%), suggesting limited influence or immediate impact on the company's strategic direction.
• The filing is an amendment to a previous filing, indicating a change or update to an existing passive position rather than a new, significant investment.

Risks

• The filing does not explicitly mention any new risks or challenges faced by Yarrow Bioscience, Inc. or the reporting persons.
• The low percentage of ownership could imply that the reporting persons are not significantly exposed to potential downside risks of Yarrow Bioscience, Inc.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding future performance or strategy for Yarrow Bioscience, Inc. or the reporting persons.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors taking passive stakes in public companies. This filing indicates Nantahala Capital Management's continued, albeit small, interest in Yarrow Bioscience, Inc. within the broader biotechnology sector.

Stakeholder Impact

• Shareholders: The filing is unlikely to have a significant immediate impact on the share price due to the small, passive ownership stake.
• Management: The filing does not indicate any intention to influence management decisions or control.

Next Steps

• The reporting persons will continue to hold their shares in the ordinary course of business.
• Any future changes in ownership exceeding reporting thresholds would necessitate further filings.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Nantahala Capital Management, Yarrow Bioscience, Investment Adviser, Common Stock, Ownership Stake